Pegorion

Quick links to important sections

Pegorion

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pegorion

Quick Facts

Property Description
Active Ingredient (INN) Macrogol (Polyethylene Glycol)
Form Powder for Oral Solution
Pharmacological Class Osmotic Laxative Agent
Common Use Regulation of bowel function
Origin Synthetic Polymer

Defining Pegorion: Identity, Class, and Composition

Pegorion is a specific pharmaceutical preparation classified as an Osmotic Laxative Agent, with the core active ingredient being Macrogol, which is the official International Nonproprietary Name (INN) for Polyethylene Glycol (PEG). This preparation is a single-ingredient product derived from a synthetic polymer that is designed to act exclusively within the digestive system. The Macrogol compounds are osmotically active macromolecules that remain non-absorbed by the body after ingestion, a characteristic that is central to its function.

Pegorion's Pharmaceutical Form and General Purpose

Pegorion is typically supplied as a flavored powder for oral solution, requiring dissolution in a liquid before being taken via the oral route of administration. The general therapeutic purpose of this preparation is to provide targeted support for the regulation of bowel function. By using its high water-binding capability, Macrogol facilitates stool softening and increases the volume of the intestinal contents.

The action of Macrogol contributes to increasing stool frequency and improving consistency in patient populations. Furthermore, its classification as an osmotic agent means that it functions as a non-systemic agent, working entirely within the gastrointestinal lumen and not entering the bloodstream. This localized and predictable action provides a targeted approach to maintaining healthy intestinal function.

What side effects are possible with Pegorion?

Possible Side Effects and Safety Information

The safety profile for Pegorion (Macrogol) is defined by officially documented adverse reactions that are primarily related to the gastrointestinal tract, which is consistent with its non-systemic, localized osmotic action. Regulatory documents classify the frequency of these effects.

Adverse Reaction Classification

The most commonly listed adverse events involve the digestive system. Reactions classified as Common often include abdominal pain, flatulence, nausea, and abdominal distension (bloating). Diarrhoea is frequently encountered, particularly with higher doses or during treatment for faecal impaction, and is often classified as Very Common. Milder diarrhoea may typically respond to a reduction in dose [1.4, 1.7].

Organ Systems and Serious Reactions

The officially documented adverse effects are grouped into several System-Organ Classes, mainly Gastrointestinal disorders and Immune system disorders. The possibility of serious adverse reactions is documented, primarily involving rare immunological events such as anaphylaxis and angioedema (severe allergic swelling) [1.1, 1.4].

Safety Considerations and Constraints

Population-Specific Safety: Caution is advised for special groups, including the elderly and individuals with impaired renal or hepatic function, due to an increased risk of fluid and electrolyte imbalances, especially during high-dose regimens [1.1, 3.6]. The labeling also notes that no effects are anticipated during pregnancy or lactation due to the drug's negligible systemic absorption [1.7].

Safety Restrictions: Regulatory constraints explicitly list conditions under which Pegorion must not be used (contraindications). These include known or suspected intestinal obstruction or bowel perforation, symptomatic ileus, toxic megacolon, and severe inflammatory bowel disease [1.7].

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory guidance for Macrogol (Polyethylene Glycol) overdose is focused on the consequences of its exaggerated osmotic effects within the gastrointestinal tract. Overdose is officially documented to present with severe diarrhoea, abdominal pain, nausea, and vomiting.


Required Emergency Actions

Overdose Outcome Action Required (Regulatory Phrasing Only)
Significant Fluid/Electrolyte Imbalance Seek immediate medical attention or contact emergency services.
Severe Dehydration/Neurological Symptoms Requires hospital monitoring and serum electrolyte monitoring.

The primary serious outcome is the development of significant fluid and electrolyte imbalance and severe dehydration, which can potentially lead to secondary neurological symptoms such as confusion or seizures. Children are noted to be at an increased risk for these severe outcomes.

Overdose Management

Treatment is restricted to symptomatic and supportive measures, as official documents state that no known specific antidote is available. Management focuses on the immediate restoration of the patient’s fluid and electrolyte balance, which may involve intravenous administration.

Therapeutic Uses of Pegorion

What Pegorion Treats: Main Uses and Benefits

Pegorion is a medication applied across domains where additional symptomatic support is needed, primarily to address symptoms related to systemic imbalance and discomfort in the digestive tract. The active substance is commonly used to help with symptoms in conditions where short-term symptomatic assistance is needed, relevant in conditions characterized by periods of heightened symptoms. It is used to manage constipation and severe symptom patterns like faecal impaction.

Pegorion assists with addressing symptom clusters that may become intense or disruptive, specifically focusing on physical discomfort associated with irregularity. It supports easing the overall symptom burden by providing supportive relief when difficulty passing stool creates noticeable physiological strain.

“Pegorion provides support that helps ease the overall symptom burden during difficult episodes.”

Therapeutic Indications

The main indications where Pegorion is applied include symptomatic relief for acute or chronic constipation and the management of faecal impaction.

Patient-Oriented Benefits

The primary benefit is that Pegorion supports easing the overall symptom load by providing symptomatic relief in settings where symptoms become momentarily overwhelming. It assists with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Functional Strain

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Pegorion — Official Regulatory Information

Populations for whom use is contraindicated

Pegorion (Macrogol 4000) must not be used if the patient has a known hypersensitivity or allergy to macrogol (polyethylene glycol) or any other ingredients listed in the product formulation.

The medicine is also strictly contraindicated for individuals with pre-existing severe conditions of the intestines, including:

  • Bowel obstruction (intestinal blockage or ileus) or symptomatic narrowing of the bowel.
  • Perforation of the digestive tract or risk of perforation.
  • Severe inflammatory bowel disease (such as ulcerative colitis, Crohn’s disease) or toxic megacolon.
  • Painful abdominal conditions of unknown cause.

Restricted or Conditional Use

  • Age Limits: While use is authorized for adults, the product is often not recommended for children under 8 years of age in some formulations, or under 2 years of age in others. When used in children, treatment for chronic constipation should not exceed 3 months due to lack of long-term clinical data.
  • Electrolyte Risk: Patients who are elderly, have existing impaired kidney or liver function, or are taking diuretics should use the medicine with caution. If diarrhea occurs in these groups, there is a risk of developing electrolyte disturbances, and medical monitoring is advised.
  • Pregnancy and Lactation: The medicine can generally be used during pregnancy and while breastfeeding as Macrogol 4000 is not significantly absorbed into the body. However, as per regulatory guidance, use should only proceed after a clear necessity has been established by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pégorion (Macrogol, Polyethylene Glycol) is a non-systemic agent, which means it is not absorbed into the bloodstream and therefore no pharmacokinetic drug-drug interactions (such as CYP-mediated or transporter-mediated) are officially documented. The established interaction profile is based on physical and pharmacodynamic effects within the digestive system.

Pharmacodynamic and Absorption-Altering Interactions

Co-administration with other substances is documented to carry two primary risks:

  • Impaired Absorption of Oral Medicines: Macrogol's action accelerates the movement of intestinal contents, potentially leading to decreased exposure of co-administered oral medications. This is clinically relevant for drugs with narrow therapeutic ranges, such as digoxin, oral contraceptives, and certain antibiotics.

  • Increased Fluid and Electrolyte Risk: Combining Pégorion with medications that also affect fluid or electrolyte balance, including diuretics, ACE inhibitors, ARBs, or NSAIDs, increases the official risk for fluid and electrolyte abnormalities and renal impairment.

Timing and Product Restrictions

Specific rules are mandated to mitigate the risk of impaired absorption. Certain critical oral medicines, including iron supplements and some antibiotics, must be administered at least 2 hours before and 6 hours after the Pégorion dose. Furthermore, starch-based food thickeners are physically incompatible with the preparation, a combination which is documented to compromise the thickening effect.

Mechanism of Action

Non-Systemic Osmotic Water Retention

Pegorion (Macrogol) operates through a physical-chemical mechanism by utilizing its high capacity for hydrogen bonding to sequester and retain water exclusively within the gastrointestinal lumen. This process is entirely non-systemic, as the inert Macrogol polymer is not absorbed into the bloodstream and does not engage with biological targets like receptors or enzymes, defining its action as a pure osmotic agent.


Faecal Hydration and Indirect Motility Enhancement

The resulting physiological effect of water retention is faecal mass hydration and a subsequent increase in luminal volume. The highly hydrated, softer stool mass acts as a volume expander, mechanically stretching the colon wall. This stretching stimulates the gut's natural muscular contractions (peristalsis), which is the secondary pathway that drives the movement of the contents forward and contributes to the final physiological consequences.

Dosage and Administration Information

How to Use Pegorion

Pegorion (Macrogol/Polyethylene Glycol) is an osmotic laxative administered via the oral route as a powder that must be fully reconstituted with water prior to ingestion. The proper use of the medicine is defined by established protocols concerning preparation, indication-specific dosing, frequency, and treatment duration.


Official Administration Guidelines

Instruction Detail
Route of Administration Oral route only, after reconstitution.
Preparation Requirements The dose must be fully dissolved in a volume of liquid, such as approximately 125 ml of water per sachet (or 4 to 8 ounces of beverage for the 17 g dose).
Frequency & Timing Typically taken once daily, or in divided doses for chronic constipation. The high-dose regimen for faecal impaction must be consumed within a 6-hour period.
Dosing (Chronic Constipation) Standard adult dosing begins at 1 sachet (e.g., 13.7 g or 17 g) and may be adjusted to a maximum of 3 sachets daily.
Dosing (Faecal Impaction) The regimen is 8 sachets daily, taken in divided doses over a brief treatment course.
Duration of Use Constraint Treatment for chronic constipation generally should not exceed 2 weeks initially. The faecal impaction course is typically limited to a maximum of 3 days.

Population and Procedural Rules

No general dose adjustment is required for use in older adults or those with renal impairment. However, specific procedural constraints apply during high-dose treatment for faecal impaction: consumption must be limited to no more than two sachets in any one hour for patients with impaired cardiovascular function. The protocol requires dissolving the full dose, ingesting the solution, and adhering strictly to the established maximum time frames for both daily intake (faecal impaction) and the overall treatment course (chronic constipation).

Recent Clinical Evidence

Research evidence / Overview of studies for Pegorion

Research Evidence for Chronic and Functional Constipation

Pegorion was studied in research exploring chronic and functional constipation, which are conditions where symptoms may vary in intensity and often involve functional limitations. The evidence base includes numerous Randomized Controlled Trials (RCTs) and authoritative systematic reviews comparing the substance to placebo and other agents. Studies reported consistent patterns where data show patterns related to higher bowel movement frequency and softer stool consistency in the observed populations. These findings describe group patterns, not personal outcomes. Follow-up durations were limited in many studies, meaning that long-term effects are not fully established.


Controlled Studies Evaluating Management of Faecal Impaction

Pegorion was also evaluated in research exploring episodes where symptoms become more noticeable, specifically for the management of faecal impaction. These were primarily short-term RCTs, predominantly involving children, that monitored the measurement of colonic clearance. Studies described patterns related to the successful clearance measurement when the substance was used as part of a short-term therapeutic plan. Data for certain groups, such as the older adult population, remain insufficient in this specific area of research.


Evidence in Specific Patient Populations

Pegorion was studied for its use in several specific patient populations beyond the general adult group. This included research in the pediatric population and in older adults, where studies monitored outcomes like stool frequency and consistency. Pegorion was also evaluated in subjects with Constipation-predominant Irritable Bowel Syndrome (IBS-C) to explore how symptoms evolved in this observed population.


Known Evidence Gaps and Areas of Uncertainty

Research provides context but not individual predictions about the sustainability of measured outcomes. Comparative evidence is lacking for a direct comparison against every available class of laxative agents, limiting the basis for evaluating differences in measured outcomes. Furthermore, long-term effects are not fully established beyond the one-year mark, and research is ongoing to further examine long-term outcomes.

Key Studies & References

  1. Public Assessment Report (PAR) for Benlaxid (Macrogol 3350/electrolytes) - (Addressing regulatory scope/indications)

Frequently Asked Questions (FAQ)

Common questions about Pegorion (FAQ)


Q: What is the main difference between Pegorion and other drugs for the same condition?

Official information describes Pegorion as an osmotic laxative. Its key characteristic is that it is a non-systemic agent, meaning the active ingredient is not absorbed into the bloodstream. It works exclusively by retaining water within the intestine to soften stool, which is a mechanism that differentiates it from other classes of drugs used for this condition.


Q: Can Pegorion be taken if you have kidney or liver issues?

Official product information advises that use is subject to caution for individuals with a history of impaired renal or hepatic function (kidney or liver issues). This caution is officially documented because there may be an increased risk of fluid and electrolyte abnormalities in these populations, particularly when higher doses are used.


Q: How quickly does Pegorion typically start working?

According to the official product information, the therapeutic effect of Macrogol generally becomes apparent within 24 to 48 hours after the first administration of the standard dose. It does not typically provide immediate relief.


Q: Does Pegorion need to be taken long-term, or just for a short period?

Regulatory documents state that treatment for chronic constipation is described as a temporary adjuvant treatment to changes in diet and lifestyle. For example, for children, the official guidelines limit the maximum course to 3 months due to a lack of longer-term data. Use should be stopped when the condition improves.


Q: Can Pegorion be safely taken alongside antacids?

Because Pegorion is a non-systemic drug, it is not involved in complex pharmacokinetic interactions like those seen with antacids affecting other drugs. However, to minimize any possibility of reduced exposure to any co-administered oral medication, timing separation (e.g., 2 hours) is often described in administration guidelines.


Q: Does Pegorion interact with common over-the-counter pain relievers like ibuprofen?

Official information documents an interaction risk between Pegorion and certain classes of medicines that affect fluid and electrolyte balance, such as NSAIDs (a drug class that includes ibuprofen). This combination is officially stated to increase the risk for fluid and electrolyte abnormalities.


Q: How long after stopping Pegorion is the substance known to remain in the body?

Official pharmacokinetic data indicates that the active ingredient, Macrogol, is not absorbed into the body and does not change chemically after ingestion. Since it is non-systemic, it passes through the gastrointestinal tract and is excreted shortly after its effect is complete.


Q: Are there any factual restrictions on activities like driving while taking Pegorion?

The official product label notes that effects on the ability to drive or operate machinery are generally not anticipated. Restrictions are typically only necessary if an individual experiences a side effect that may impair function.


Q: Why is Pegorion generally not recommended for use in children?

While use is permitted in some pediatric groups, official guidelines restrict treatment for chronic constipation to not exceed 3 months. This time limit is due to an officially acknowledged lack of clinical data for longer treatment durations in the pediatric population.


Q: Why do doctors prescribe Pegorion if my symptoms have already improved?

Pegorion is indicated for the symptomatic treatment of constipation and is often described as part of an adjuvant treatment plan, meaning it works alongside lifestyle changes. Official guidance is that use should be stopped when the condition improves and only resumed if symptoms recur.


Q: What is the usual recommended length of time people take Pegorion for?

Official guidelines place limits on initial use (e.g., maximum two weeks) and chronic use in children (maximum three months). Beyond these official constraints, the medicine is defined as a temporary adjuvant treatment that is used to manage symptoms, rather than for a fixed, long-term duration.


Q: Is it okay to drink coffee or tea while taking Pegorion?

Yes, official administration guidelines indicate that the powder may be dissolved in a variety of hot or cold beverages, including water, tea, or cordial. Normal food and drink consumption is generally permitted while taking the medicine.


Q: Is Pegorion safe for people over the age of 65?

Official product information states that use is subject to an official caution for the elderly population. This is specifically due to a documented risk of fluid and electrolyte disturbances in older adults, especially if diarrhea occurs.


Q: Are there any known foods that interact with Pegorion?

Regulatory documents specifically state that co-administration is documented to compromise the thickening effect of starch-based food thickeners. The combination of the two products is considered physically incompatible.


Q: Is Pegorion a newly approved medication?

The core active ingredient, Macrogol (Polyethylene Glycol), has a long history of medical use, dating back to the 1980s for bowel preparation. It was first officially approved for general medical use in the US in 1999.


Q: Does the body develop a tolerance to Pegorion over time?

Clinical evidence indicates that responses to treatment are often durable, meaning the effect can be maintained without the need for constantly increasing the dosage. This suggests that the body does not typically develop pharmacological tolerance to the active ingredient.


Q: What are the factual guidelines for storing Pegorion?

Official regulatory guidelines require that the product must be stored below 25 C and kept out of the sight and reach of children. Additionally, once the powder is mixed with water, the solution must be used within 24 hours.


Q: Can I take vitamins, herbal products, or supplements with Pegorion?

As a general principle, the accelerating effect of Macrogol on intestinal transit may lead to decreased exposure of any orally taken substance, including vitamins and supplements. A timing separation (e.g., 2 hours) is often cited in administration guidelines to mitigate this effect.


Q: Is there a generic equivalent for Pegorion currently available?

Yes, the active ingredient in Pegorion, Macrogol (Polyethylene Glycol), is widely available as a generic medication and over-the-counter preparation in many regions worldwide.


Q: Has Pegorion been approved by major regulatory bodies outside the US?

Yes, the active ingredient is officially approved and available as a prescription or over-the-counter medicine in major regions, including the UK, Europe, Australia, and Canada.


Q: What are the facts regarding taking Pegorion with alcohol?

Official information from health authorities indicates that the consumption of alcohol is generally permitted while taking the medicine. No specific warnings or contraindications regarding alcohol are typically documented in the official labeling.


Q: Is Pegorion a drug that requires a special prescription or monitoring program?

Depending on the specific formulation and the country, Pegorion can be classified as either a Prescription-Only Medicine (POM) or it may be available for purchase as an Over-The-Counter (OTC) medicine without a prescription.


Q: Is it possible for Pegorion to suddenly lose its effectiveness?

Clinical data suggests that tolerance does not typically develop. However, efficacy relies on adequate fluid intake and the absence of certain underlying gastrointestinal conditions (such as obstruction), which are officially listed as contraindications for its use.

How should Pegorion be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documentation defines specific requirements for the storage and disposal of Pegorion (macrogol 4000).

Storage Conditions

Condition Requirement
Temperature Store below 25 C.
Prohibited Do not refrigerate or freeze.
Protection Keep in the original sachet until use.
Child Safety Store out of the sight and reach of children.

Stability and Handling

Once the powder is reconstituted (mixed with water), the prepared solution has a limited shelf-life and must be used within 24 hours.

Disposal Rules

Unused Pegorion and any waste materials must be disposed of in accordance with local requirements for pharmaceutical waste. The product should not be disposed of via household waste or wastewater (such as flushing down a toilet or pouring down a sink) to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pegorion found in:

A-Z Index: